Okada N, Miyamoto H, Yoshioka T, Katsume A, Saito H, Yorozu K, Ueda O, Nakagawa S, Ohsugi Y, Mayumi T
Faculty of Pharmaceutical Sciences, Osaka University, Japan.
Biol Pharm Bull. 1997 Mar;20(3):255-8. doi: 10.1248/bpb.20.255.
We previously demonstrated that IgG1 plasmacytosis in human interleukin-6 transgenic mice (hIL-6 Tgm) was suppressed by the implantation of SK2 hybridoma cells (SK2 cells, which secrete anti-hIL-6 monoclonal antibodies) microencapsulated in a semipermeable and biocompatible device. In this study, we demonstrated that the mesangio-proliferative glomerulonephritis in hIL-6 Tgm was also improved by the same treatment. These results strongly support the concept of cytomedicine, which is a novel drug delivery system (DDS) using living cells. However, an electron microscopy study showed that cytomedicine has a limited duration of effectiveness because of the disappearance of space for cell proliferation in the microcapsule. Thus, the control of cell proliferation in a device must be developed to prolong the function and effectiveness of cytomedicine.
我们之前证明，将包封在半透性生物相容性装置中的SK2杂交瘤细胞（分泌抗人白细胞介素-6单克隆抗体的SK2细胞）植入人白细胞介素-6转基因小鼠（hIL-6 Tgm）中，可抑制其IgG1浆细胞增多症。在本研究中，我们证明相同的治疗方法也改善了hIL-6 Tgm中的系膜增生性肾小球肾炎。这些结果有力地支持了细胞医学的概念，这是一种使用活细胞的新型药物递送系统（DDS）。然而，一项电子显微镜研究表明，由于微胶囊中细胞增殖空间的消失，细胞医学的有效性持续时间有限。因此，必须开发一种控制装置中细胞增殖的方法，以延长细胞医学的功能和有效性。
